Fierce Pharma

MARCH 4, 2024

After decades of research into respiratory syncytial virus (RSV), Pfizer and GSK’s groundbreaking vaccines made waves as the first immunizations against the common respiratory illness.

Safety 287

Safety FDA 287

Fierce Pharma

APRIL 26, 2024

GSK pulls Pfizer and BioNTech into another vaccine patent lawsuit, this time surrounding the partners' mRNA-based COVID shots fkansteiner Fri, 04/26/2024 - 10:07

230

230

Fierce Pharma

NOVEMBER 28, 2023

As the pandemic eased earlier this year, officials in Poland became vocal critics of the financial obligations laid down by Pfizer’s large vaccine supply pact with the European Union. | Now, months after the country asked for a reprieve from the costs imposed by the 2021 agreement, Pfizer is targeting Poland in court.

344

344

Fierce Pharma

OCTOBER 9, 2023

Following similar initiatives to bolster mRNA vaccine production and access in Africa, the Bill & Melinda Gates Foundation is providing new funding to a clutch of drugmakers.

345

345

Fierce Pharma

JUNE 12, 2023

Two years after the initial COVID-19 vaccine push swept across the globe, Pfizer’s COVID-19 vaccine partner BioNTech is heading to court in its home country of Germany to defend itself against alle | The drugmaker will defend itself against claims from a German healthcare worker who sued the company for at least 150,000 euros ($161,500).

Healthcare 357

Healthcare Healthcare 357

Fierce Pharma

NOVEMBER 28, 2023

Armed with a full FDA approval after four years supplying its anthrax vaccine under a pre-emergency use authorization, Emergent BioSolutions is expanding its countermeasure supply pact with the Uni | Armed with a full FDA approval after four years supplying its anthrax vaccine under a pre-emergency use authorization, Emergent BioSolutions is expanding (..)

FDA 312

FDA 312

Fierce Pharma

SEPTEMBER 12, 2023

The CDC wants to reset expectations for flu vaccines to correct falling uptake. | The CDC wants to reset expectations for flu vaccines to correct falling uptake.

324

324

Fierce Pharma

NOVEMBER 21, 2023

With litigation spanning many countries, the COVID-19 vaccine giants remain engaged in a heated patent war. Moderna pledged to appeal after the European Patent Office ruled one of its patents invalid in the intellectual property battle that spans multiple countries.

363

363

Fierce Pharma

SEPTEMBER 25, 2023

While GSK’s Arexvy was first out the gate in this summer’s respiratory syncytial virus (RSV) vaccine race, Pfizer has kept the pressure up with its rival shot Abrysvo. While GSK’s Arexvy was first out the gate in this summer’s respiratory syncytial virus (RSV) vaccine race, Pfizer has kept the pressure up with its rival shot Abrysvo.

287

287

Fierce Pharma

JANUARY 19, 2024

The lawsuit marks the latest move in Pfizer’s campaign to press countries to honor COVID-19 vaccine contracts inked by the European Commission in May 2021. . | Following public spats with Hungary and Poland, Pfizer and its German mRNA partner BioNTech have kicked off legal proceedings against Romania.

320

320

Fierce Pharma

SEPTEMBER 11, 2023

The FDA has approved Pfizer and Moderna’s separate vaccine formulations that target current variants of the disease. Out with the old and in with the new: Monday, the U.S. | Each company’s shot is approved for people ages 12 and up and emergency authorized for patients 6 months old to 11 years old.

FDA 363

FDA Patients 363

Fierce Pharma

NOVEMBER 10, 2023

The FDA has approved the world’s first chikungunya vaccine, giving a thumbs-up to Valneva’s Ixchiq. Valneva has won the race in the U.S. | The French company receives a priority review voucher from the FDA, which it said it will sell. It is an accelerated approval and subject to a confirmatory, real-world study.

FDA 285

FDA 285

Fierce Pharma

OCTOBER 24, 2023

On the market for two decades, AstraZeneca’s nasal spray flu vaccine, FluMist, may become available for self-administration as soon as next year. | On the market for two decades, AstraZeneca’s nasal spray flu vaccine, FluMist, may become available for self-administration as soon as next year.

FDA 287

FDA Marketing 287

Fierce Pharma

NOVEMBER 3, 2023

Pfizer is cutting roughly 200 positions at its Kalamazoo site following a review of demand for its COVID-19 vaccine and antiviral Comirnaty and Paxlovid. Pfizer’s plunging COVID-19 product demand has spurred a companywide cost-cutting campaign, with nearly 200 jobs now on the chopping block in Michigan.

354

354

Fierce Pharma

AUGUST 15, 2023

As COVID-19 vaccine makers gear up to launch updated shots in the private market, can the new vaccines keep up with the virus? zbecker Tue, 08/15/2023 - 09:48

Marketing 246

Marketing 246

Fierce Pharma

NOVEMBER 1, 2023

Besides Pfizer’s fast-declining COVID-19 sales, vaccine rival GSK is giving the New York drugmaker another reason to worry. In the first round of their RSV vaccine showdown, GSK's Arexvy pulled down $860 million, more than doubling the haul from Pfizer's Abrysvo.

Sales 292

Sales 292

Fierce Pharma

SEPTEMBER 26, 2023

WuXi Vaccines launched its first standalone vaccine contract manufacturing facility in Suzhou. Amid a global expansion spree at WuXi Biologics, the company's immunization-focused subsidiary has christened its inaugural CDMO site in China.

Manufacturing 303

Manufacturing 303

Fierce Pharma

APRIL 18, 2024

And its top priority is the launch of a chikungunya vaccine.

Manufacturing 146

Manufacturing 146

Fierce Pharma

JULY 19, 2023

While vaccines for COVID-19 have certainly enjoyed the spotlight in recent years, rates of uptake for other shots have sharply declined. | The GSK-funded report looked at adult vaccination data and found a major slump in vaccine adoption over the last few years, save for COVID vaccines.

246

246

Fierce Pharma

JANUARY 30, 2024

After 'bad launch' remark by CEO, Pfizer's RSV vaccine gains traction in Q4. How will it fare in latest round of GSK showdown? kdunleavy Tue, 01/30/2024 - 08:58

315

315

Fierce Pharma

APRIL 4, 2024

Sanofi pledges to keep polio vaccine supplies afloat in India after new approval fkansteiner Thu, 04/04/2024 - 16:04

195

195

Fierce Pharma

APRIL 19, 2023

Goodbye, original COVID-19 vaccines: FDA updates shot guidance, pulls monovalent authorizations zbecker Wed, 04/19/2023 - 11:04

FDA 364

FDA 364

Fierce Pharma

JANUARY 26, 2023

BMS settles lawsuit with two fired employees who refused COVID vaccines kdunleavy Thu, 01/26/2023 - 14:30

361

361

Fierce Pharma

APRIL 10, 2023

New WHO recommendations on COVID vaccines create more revenue uncertainty: analyst kdunleavy Mon, 04/10/2023 - 10:47

319

319

Fierce Pharma

NOVEMBER 10, 2022

AstraZeneca withdraws US COVID vaccine application, shifts focus to antibody treatments. Thu, 11/10/2022 - 09:02.

364

364

European Pharmaceutical Review

MARCH 26, 2024

Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition. Moderna’s Spikevax XBB.1.5-adapted

Safety 97

Safety Leads Patients Pharmaceutical 97

MedCity News

FEBRUARY 21, 2024

Bavarian Nordic will concentrate on its portfolio and pipeline of infectious diseases vaccines, including top seller Jynneos, approved for mpox and smallpox. The company only had one clinical-stage cancer vaccine program.

Biopharma 118

Biopharma Pharma 118

European Pharmaceutical Review

NOVEMBER 1, 2023

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development. 1 WHO’s analysis was stark.

Safety 105

Safety Marketing Manufacturing Government 105

European Pharmaceutical Review

JANUARY 26, 2024

A paper, published in Nature Chemical Biology has reported the first ‘free-from ‘tree’ production of a key vaccine ingredient sourced from the soapbark tree. Bioengineering vaccine adjuvants The paper explained: “QS-21 is a potent vaccine adjuvant currently sourced by extraction from the Chilean soapbark tree.

Pharmaceutical 87

Pharmaceutical 87

MedCity News

FEBRUARY 22, 2024

The arbitration hearing over the disputed vaccine purchase agreement with Gavi was scheduled for this summer. By settling now and agreeing to deferred payments over the next five years, Novavax avoids the risk of being responsible for a much bigger payout all at once.

Biopharma 127

Biopharma Pharma 127

European Pharmaceutical Review

MARCH 14, 2024

Overall, the goal of expanded facility is to strengthen [SK biosciences] manufacturing capabilities for global supply [of the pneumococcal conjugate vaccine candidate GBP410]” SK bioscience has announced its manufacturing plant L HOUSE, in Andong, Gyeongsangbuk-do, South Korea, is set to have a facility expansion.

Manufacturing 89

Manufacturing Marketing Medicine Pharma 89

European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Distribution 106

Distribution Manufacturing Food Specialization 106

pharmaphorum

APRIL 16, 2024

FDA starts review of GSK’s 5-in-1 meningitis vaccine, cueing up a decision early next year, as it tries to chase down Pfizer's recently-approved Penbraya

FDA 101

FDA 101

European Pharmaceutical Review

OCTOBER 4, 2023

The World Health Organization ( WHO ) has recommended a new vaccine, R21/Matrix-M, to prevent malaria in children. The R21 vaccine is the second malaria vaccine recommended by WHO. This follows the WHO’s recommendation of the RTS,S/AS01 vaccine for the disease in 2021.

Manufacturing 105

Manufacturing Pharmaceutical 105

Pharmaceutical Technology

FEBRUARY 12, 2024

vaccine targeting Omicron variant. The UK MHRA has granted approval for a variation in licence of Pfizer-BioNTech’s Comirnaty XBB.1.5

142

142

PharmaTimes

APRIL 19, 2024

Both will develop cancer vaccine candidates in selected haematological and solid tumour indications

93

93

Pharmaceutical Technology

JANUARY 29, 2024

The rapid sequencing of the SARS-CoV-2 and the subsequent development of mRNA vaccines led to the authorisation of the first of these vaccines in late 2020.

Leads 111

Leads 111